<DOC>
	<DOCNO>NCT02279732</DOCNO>
	<brief_summary>The purpose study determine whether Ipilimumab plus Paclitaxel Carboplatin extend life patient squamous non small cell lung cancer placebo plus Paclitaxel Carboplatin .</brief_summary>
	<brief_title>Phase 3 Trial Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel Carboplatin Versus Placebo Plus Paclitaxel Carboplatin</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Subjects NSCLC predominantly squamous histology document histology cytology brushing , wash needle aspiration define lesion sputum cytology alone Stage IV Recurrent NSCLC ( per 7th International Association Study Lung Cancer ( IASLC ) classification ) At least 1 measurable tumor lesion , define mWHO criterion , locate previously irradiate area Eastern Cooperative Oncology Group ( ECOG ) performance status â‰¤1 Brain metastasis Malignant pleural effusion recurrent Documented history severe autoimmune immune mediate symptomatic disease require prolong ( 2 month ) systemic immunosuppressive ( ie , steroid ) treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>